Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG1MW2)

• Drug Name: Elranatamab Drug Info
• Synonyms: PF-06863135

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]

• Cross-matching ID: TTD Drug ID: DMG1MW2

Molecule-Related Drug Atlas

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[2]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[3]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[4]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[5]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[6]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[7]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[8]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[9]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[10]
TAK-280	DM08RE5	Aggressive cancer	2A00-2F9Z	Phase 2	[11]

Drug(s) Targeting B-cell maturation protein (TNFRSF17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Idecabtagene vicleucel	DMP1QTS	Multiple myeloma	2A83	Approved	[12]
Belantamab mafodotin	DMBT3AI	Multiple myeloma	2A83	Approved	[13]
Teclistamab	DMGR8JI	Multiple myeloma	2A83	Approved	[14]
Ciltacabtagene autoleucel	DMU2J7Y	Multiple myeloma	2A83	Phase 3	[15]
Bb2121	DMB0UF9	Multiple myeloma	2A83	Phase 2	[16]
LCAR-B38M CAR-T Cell	DMQZJNA	Multiple myeloma	2A83	Phase 2	[17]
Descartes-08	DM63P1W	Multiple myeloma	2A83	Phase 2	[18]
Descartes-11	DM1UO4S	Multiple myeloma	2A83	Phase 2	[19]
CART-19/BCMA	DMVW1GY	Multiple myeloma	2A83	Phase 1/2	[20]
AUTO2	DM0PWX2	Multiple myeloma	2A83	Phase 1/2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell maturation protein (TNFRSF17)	TTZ3P4W	TNR17_HUMAN	Not Available	[1]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Not Available	[1]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [2] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [3] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [4] Clinical pipeline report, company report or official report of Genmab.
• [5] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [6] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [7] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [8] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [9] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [10] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
• [11] ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
• [13] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [14] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761291.
• [15] ClinicalTrials.gov (NCT04181827) A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). U.S. National Institutes of Health.
• [16] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [17] ClinicalTrials.gov (NCT03758417) A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
• [18] ClinicalTrials.gov (NCT03448978) Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma
• [19] Clinical pipeline report, company report or official report of Cartesian Therapeutics.
• [20] ClinicalTrials.gov (NCT03455972) Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT
• [21] ClinicalTrials.gov (NCT03287804) APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma